Krystal Biotech is a clinical-stage gene therapy company using its proprietary Skin TARgeted Delivery (STAR-D) platform to develop treatments for skin diseases. Its lead product candidates include B-VEC, KB105, and KB301 for the treatment of rare dermatological conditions. The company focuses on diseases such as dystrophic EB, Netherton syndrome, TGM1-deficient ARCI, cystic fibrosis, aesthetic skin conditions, and chronic skin diseases.